This webinar is being postponed … new date to be confirmed
IUPAC webinar series on Entrepreneurship and Chemistry
Thu, July 23, 2026 | 2:00 pm BST / 3:00 pm CEST / 9:00 am EDT
by Marc Güell, Pompeu Fabra University, Spain
- How his team developed a gene-writing platform for human cells and deployed it both ex vivo (T cells) and in vivo (liver targeting).
- How Cutibacterium acnes can be used as a chassis for engineering human skin properties, opening new possibilities for dermatological and cosmetic applications.
About Marc Güell
Scientific excellence and impact has defined Marc’s career. He has a strong record of original, solid, ambitious and scientifically and socially relevant research. His work includes several synthetic biology breakthroughs (highest number of CRISPR edits in a mammal, most recoded genome, PERVs-free pigs, effective gene writing, first skin microbiome modification proof of concept, AI-generated novel gene therapy tools) that have produced tremendous impact (>22,000 citations, companies developing therapies) and he is developing new tools that could revolutionize therapeutic approaches to several medical conditions.
An important part of Marc’s research is being translated into relevant technology transfer. He is the cofounder and founding scientist of three companies [Sbiomedic (in clinical phase for acne; acquired in 2022 by Beiersdorf), eGenesis (xenotransplant, first pig kidney to human), Integra Tx (gene therapy)]. A 4th company is currently in ‘stealth mode’ (Thesian bio; in vivo CAR-T). He is also the inventor of patents licensed to leading biotech companies (Editas Medicine, Verve Therapeutics, Genentech, …). (ORCID 0000-0003-4000-7912)
Facilitator:
Joaquim L Faria
Full Professor, University of Porto
Scientific coordinator, LSRE-LCM
President, Portuguese Chemical Society, SPQ
See originating project ‘Chemistry Entrepreneurship’ chaired by Bipul Saha and Hemda Garelick, and members of IUPAC Executive Board.
Feature photo by John Salvino on Unsplash


